Evidence map›Paper›PMID 40117033›Full record

ArticleIrish journal of medical science2025

Prognostic value of progesterone receptor expression in non-small cell lung cancer tissue.

Romanov I P, Bogush T A, Scherbakov A M, Grishanina A N, Bogush E A, Ravcheeva A B, Kosorukov V S

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Romanov I PN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. biosophy@yandex.ru.ORCID http://orcid.org/0000-0002-9931-1153
Bogush T AN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID http://orcid.org/0000-0002-7673-4284
Scherbakov A MN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID http://orcid.org/0000-0002-2974-9555
Grishanina A NN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID http://orcid.org/0000-0002-4277-9222
Bogush E ASechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID http://orcid.org/0000-0001-5601-3669
Ravcheeva A BN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID http://orcid.org/0000-0001-5969-0219
Kosorukov V SN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.ORCID http://orcid.org/0000-0002-8462-2178

Funding

Ministry of Health of the Russian Federation 123021500076-3Ministry of Science and Higher Education of the Russian Federation 075-15-2021-1060
6 · The paper itself

Abstract

backgroundProgesterone receptors (PRs) play a role in the regulation of cell proliferation and are expressed in non-small cell lung cancer (NSCLC) tissue. Therefore, they represent a potential target for novel antitumor therapies. A survival analysis of NSCLC patients based on PR expression in tumor tissue may help assess the feasibility of using PR modulators in the treatment of this disease.

aimThis study aims to evaluate the prognostic significance of PR expression in NSCLC to determine the potential utility of PR modulators as a therapeutic strategy.

methodsPR expression was assessed in 130 surgically resected NSCLC samples using immunofluorescence analysis combined with flow cytometry. Primary antibodies against PR (NBP2-4638, Novus Biologicals, USA) and secondary antibodies conjugated with DyLight650 (ab98729, Abcam, UK) were used. The percentage of PR-expressing cells was quantified using FlowJo software. Statistical analyses were conducted in GraphPad Prism and RStudio using the "survival" package. The prognostic impact of PR expression in NSCLC tissue was evaluated in the overall patient cohort and after excluding censored events (n = 56) to minimize the influence of confounding factors on survival analysis.

resultsAfter excluding censored events and stratifying patients based on the median PR expression level (57%), survival analysis revealed that high PR expression in NSCLC tissue is associated with a poorer prognosis (p = 0.05). Patients with high PR expression (≥ 57%) had a median survival of 12.8 months, whereas those with low PR expression (< 57%) had a median survival of 25.8 months (HR = 1.7).

conclusionsElevated PR expression in NSCLC tumors is associated with reduced patient survival. These findings suggest that PR modulators may have potential therapeutic value for NSCLC patients with PR-positive tumors.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, ProgesteroneAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisSurvival AnalysisBiomarkers, TumorReceptors, ProgesteroneFlow cytometryNon-small cell lung cancerProgesterone receptorsSurvival analysis

Identifiers

PMID40117033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.